ArriVent BioPharma, Inc. AVBP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s accrued expenses?
- ArriVent BioPharma, Inc. (AVBP) reported accrued expenses of $16.17M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s accrued expenses changed year-over-year?
- ArriVent BioPharma, Inc.'s accrued expenses increased by 91.3% year-over-year, from $8.45M to $16.17M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s accrued expenses?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s accrued expenses has grown at a 69.6% compound annual growth rate (CAGR), from $6.95M to $20M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.